Results 91 to 100 of about 19,009 (196)

Additional file 1 of Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis

open access: yes, 2020
Additional file 1: Figure S1. Azacitidine vs. conventional care regimens (direct evidence-RR). Figure S2. Azacitidine vs. conventional care regimens (direct evidence-OR). Figure S3. Decitabine vs. conventional care regimens (direct evidence-RR).
Bingbing Wen (8583942)   +3 more
core   +1 more source

Decitabine reverses TGF-β1-induced epithelial–mesenchymal transition in non-small-cell lung cancer by regulating miR-200/ZEB axis

open access: yes, 2017
Nan Zhang,* Yanyang Liu,* Yuyi Wang, Maoyuan Zhao, Li Tu, Feng Luo Department of Medical Oncology, Cancer Center, Lung Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s ...
Liu Y   +5 more
core  

Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML

open access: yesNature Communications, 2019
In acute myeloid leukemia, hypomethylating agents decitabine and azacytidine are used interchangeably. Here, the authors show that the major metabolite of decitabine, but not azacytidine, is subject to SAMHD1 inactivation, highlighting SAMHD1 as a ...
Thomas Oellerich   +23 more
doaj   +1 more source

KRAS Mutations Predict Inferior Post‐Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations

open access: yesEuropean Journal of Haematology, Volume 117, Issue 5, Page 1318-1326, November 2026.
ABSTRACT Somatic mutations in the MAPK signaling pathway are frequently identified at AML diagnosis; however, their impact on treatment resistance and long‐term survival remains unclear. We conducted a retrospective study of patients with newly diagnosed MAPK‐mutated AML seen at the University of Iowa Health Care.
Kensuke Takaoka   +6 more
wiley   +1 more source

Dose‐Adjusted Treatment With 7‐Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia

open access: yesEuropean Journal of Haematology, Volume 117, Issue 5, Page 1358-1368, November 2026.
ABSTRACT Acute myeloid leukaemia (AML) in older or unfit patients is commonly treated with hypomethylating agents (HMA) plus venetoclax (VEN), but prolonged VEN exposure often causes substantial haematological toxicity. We retrospectively analysed 61 elderly AML patients treated with HMA + VEN for 7 (7d), 14 (14d) or > 14 days (> 14d) per cycle.
Laurenz Steiner   +12 more
wiley   +1 more source

Control of Gemcitabine Activity With Blue and Red Light

open access: yesChemistry – A European Journal, Volume 32, Issue 38, 13 October 2026.
Treating cancer with chemotherapy is generally associated with many side effects, which can be addressed by selectively releasing the desired drugs with visible light. Sixteen new blue light‐activatable cytostatics were introduced, with the gemcitabine derivative exhibiting ideal properties.
Nils F. Kersten   +6 more
wiley   +1 more source

Decitabine-Induced Demethylation of 5′ CpG Island in GADD45A Leads to Apoptosis in Osteosarcoma Cells

open access: yes, 2008
GADD45 genes are epigenetically inactivated in various types of cancer and tumor cell lines. To date, defects of the GADD45 gene family have not been implicated in osteosarcoma (OS) oncogenesis, and the role of this pathway in regulating apoptosis in ...
Khaldoun Al-Romaih   +5 more
core   +1 more source

Comparison of clinical efficacy between decitabine combined with half the amount of CAG regimen with CAG regimen alone in patients with inermediate to high-risk myelodysplastic syndrome

open access: yesBIO Web of Conferences, 2017
Objective: To investigate the efficacy and safety of decitabine combined with half the amount of CAG and CAG regimen alone. Methods: Comparison the effectiveness, overall survival and incidence of adverse reactions of 42 cases of MDS used decitabine ...
Fan Zhenwei   +4 more
doaj   +1 more source

Enhanced induction of fetal hemoglobin by the combination of decitabine with RN-1 in β-thalassemia/HbE erythroid progenitor cells

open access: yesMolecular Medicine
Background Fetal hemoglobin (HbF; α2γ2) induction is a well-established approach for β-hemoglobinopathies, including sickle cell disease (SCD) and β-thalassemia.
Tiwaporn Nualkaew   +9 more
doaj   +1 more source

A multiomics approach reveals RNA dynamics promote cellular sensitivity to DNA hypomethylation

open access: yesScientific Reports
The search for new approaches in cancer therapy requires a mechanistic understanding of cancer vulnerabilities and anti-cancer drug mechanisms of action.
Alex Y. Ge   +14 more
doaj   +1 more source

Home - About - Disclaimer - Privacy